Clinical trials
Positron Emission Tomography clinical trials
Below are recruiting positron emission tomography clinical trials, each written for real people, not researchers. We’re tracking 357 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07105878Recruiting
Epidural stimulation for spinal cord injury recovery
This trial tests whether an implanted device that sends electrical pulses to the spinal cord can help people with spinal cord injuries regain movement. It is for those who have not seen recent improvement with rehab.
Hangzhou, ZhejiangAges 16–60 - NCT07121595RecruitingPhase 2
Personalized neck radiation for mouth cancer with sentinel node biopsy
This study tests whether a personalized approach to radiation therapy after surgery, guided by a special lymph node biopsy (sentinel node biopsy), can effectively treat mouth cancer while reducing side effects. It is for people whose cancer is on one side of the mouth and has not spread to the other side of the neck or beyond.
Ann Arbor, MichiganAges 18 years+ - NCT07138820Recruiting
Comparing scans to find parathyroid gland disease
This study compares a newer type of scan (18F-choline PET/CT) to standard imaging to help doctors locate overactive parathyroid glands. The goal is to see if the newer scan works better for planning surgery in people with primary hyperparathyroidism.
LundAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for treating meningioma that has come back or grown
This trial tests a new drug, RYZ101, for people with a type of brain tumor called meningioma that has returned or gotten worse after initial treatment. It may be an option if your tumor shows up on a special scan and you have tried at least one standard treatment.
Columbus, OhioAges 18 years+ - NCT07164027RecruitingEarly Phase 1
Comparing a new PSMA scan to MRI for prostate cancer detection
This trial tests whether a new imaging agent (flotufolastat F 18 PET CT) can find prostate cancer better than MRI. If you have a suspicious spot on an MRI, this study may help doctors see if the new scan is more accurate.
Los Angeles, CaliforniaAges 18–90 - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+ - NCT07185165RecruitingPhase 2
PET Scan for Prostate Cancer Recurrence After Focal Therapy
This study uses a special PET/CT scan (Flotufolastat F 18) to look for leftover or returning prostate cancer after you've had a targeted treatment called focal therapy. The goal is to see if the scan can help find cancer that might need further treatment.
Los Angeles, CaliforniaAges 18–90 - NCT07207798Recruiting
Epidural spinal stimulation for spinal cord injury (T11-L3)
This trial tests whether epidural electrical stimulation can help people with spinal cord injury between T11 and L3 improve their walking ability. It is for those injured between 2 and 24 months ago who currently have limited walking function.
Hangzhou, ZhejiangAges 16–65 - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07224100RecruitingPhase 2
Chemo plus targeted drug for newly diagnosed Ph+ ALL
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
Seattle, WashingtonAges 18 years+ - NCT07227571RecruitingPhase 1
CAR T cells for advanced osteosarcoma
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Seattle, WashingtonAges 1–75 - NCT07306052Recruiting
Spinal cord stimulation to help walk again after injury
This trial tests whether placing a small device on the spinal cord can help people with spinal cord injuries regain the ability to walk. It is designed for those who have had a traumatic injury and still have some movement in their upper body.
Hangzhou, ZhejiangAges 16–70 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT04857528Recruiting
Testing HPV DNA in anal and cervical tumors
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
Chicago, IllinoisAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT05304585RecruitingPhase 3
Chemo for children with early, low-risk fusion-negative rhabdomyosarcoma
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Birmingham, AlabamaAges Up to 21 years - NCT05518903RecruitingPhase 2
Scan test to see tumor-support cells in pancreatic cancer
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Rochester, MinnesotaAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06323460RecruitingPhase 2
Less Radiation for HPV Throat Cancer Guided by a Blood Test
This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.
Columbus, OhioAges 18 years+ - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+
Hear when a new Positron Emission Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for positron emission tomography?
- Yes. Clin2 currently lists 357 recruiting positron emission tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a positron emission tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a positron emission tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.